Skip to main content
. 1998 Apr;18(4):2344–2359. doi: 10.1128/mcb.18.4.2344

FIG. 8.

FIG. 8

Elevation of ErbB-2 and ErbB-3 expression during tumor progression in the mutant PyV MT strains. (A) Immunoblot analyses of mammary epithelial hyperplasias (HP) or breast tumors (BT) from the MT-Y315/322F strain. One hundred micrograms of total protein lysate for four different hyperplasias (2480, 7184, 8786, and 8789) and tumors (7450, 7887, 8673, and 8064) was subjected to immunoblot analyses with either ErbB-2- or ErbB-3-specific antibodies. (B) Immunoblot analyses of mammary epithelial hyperplasias or breast tumors from the MT-Y250F strain. Sixty micrograms of total protein lysate for four different hyperplasias (8137, 8814, 8458, and 9086) or breast tumors (8809, 8566, 6879, and 9687) was subjected to immunoblot analyses with either ErbB-2 or ErbB-3.